Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD Phase 3 study in biliary atresia is over 50% enrolled – ASSERT Phase 3 study in Alagil